Under one in 10 individuals that would benefit from GLP-1 drugs including Wegovy can access them, warns the WHO as it publishes its initial guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for more widespread and fairer availability to these injectable treatments.
Per projections, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"Our latest guidelines affirms that obesity is a long-term condition that can be managed with comprehensive and ongoing care," said its chief Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and logistical bottlenecks are major barriers to broad availability to the treatments that can help people shift substantial body mass, notes the organization.
GLP-1 Therapy Scarcity
Despite the present most optimistic outlook, the supply of GLP-1 therapies might only reach approximately 100 million people – under 10% of eligible patients, as stated by the health organization.
The advice urges governments and firms to increase availability, via strategies like voluntary licensing.
A patent on semaglutide – the main ingredient of a leading brand – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Work
These medications replicate a natural hormone to reduce digestion speed, curb appetite and increase the sense of being full so individuals reduce food intake.
People usually begin shedding pounds in the initial weeks of commencing the once-weekly jabs.
Evidence indicates patients may put most of the weight back on after a year of halting the treatment, because their typical hunger return.
Being overweight or obese elevates your likelihood for contracting medical conditions, including diabetes, heart disease, brain attack, and certain malignancies.
Excess weight concerns people in all nations and was responsible for 3.7 million deaths worldwide in 2024, according to the WHO.
